Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer

International Journal of Hematology-Oncology and Stem Cell Research

Volumn 7, Issue 4, 2013, Pages 24-28

  Basi, Ali ^a   Sohrabkhani, Shahab ^a   Zamani, Farhad ^a   Baghai Wadji, Masoud ^a   Razavi, Seyyed Mohsen ^a   Ajdarkosh, Hossein ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemotherapy; Gastroesophageal junction; Mortality; Surgery

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONTINUOUS INFUSION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 84885206276     PISSN: 17351243     EISSN: 20082207     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533-543.
2. Levi F, Lucchini F, Negri E et al. Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. Int J Cancer 2004; 110: 155-169.
3. Levi F, Lucchini F, Gonzalez JR et al. Monitoring falls in gastric cancer mortality in Europe. Ann Oncol 2004; 15: 338-345.
4. Engstrom PF, Lavin DT, Douglass HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group (EST 3275). Cancer 1985; 55: 1868-1873.
5. Coombes RC, Schein PS, Chilvers CED et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-1369.
6. Meyerhardt JA, Fuchs CS. Adjuvant therapy in gastric cancer: can we prevent recurrences? Oncology 2003; 17: 714-722.
7. Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8: 1-11
8. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J (1990) Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 19: 1357-1362
9. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1; 29(13):1715-1721. Epub 2011 Mar 28.
10. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004 Aug; 30(6):643-649.
11. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20.